SmallCap 60: Ortho Regenerative (ORTH: CSE) (ORTIF: OTCQB) Is pleased with recent progress of U.S. Phase I/II clinical trial related activities

Targeting the $5 BILLION Soft Tissue Repair Market

Chitogenx is in the regulatory lead for regenerative products + signs MOU with major Medical Institute

Reply New Message

Prev Message Back To Forum Threaded View Next Message

AGORACOM-BM

Rank: Administrator [?]

Points: 25775 [?]

Votes: 3 Score: 5.0 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

SmallCap 60: Ortho Regenerative (ORTH: CSE) (ORTIF: OTCQB) Is pleased with recent progress of U.S. Phase I/II clinical trial related activities

posted on Jun 24, 2022 04:33PM

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply